Device Industry Mindful Of AHRQ Cost-Effectiveness Agenda, Due June 8
This article was originally published in The Gray Sheet
Executive Summary
The device industry will discuss with AHRQ the need to consider long-term costs of new technology underutilization as the agency develops its cost-effectiveness research agenda
You may also be interested in...
Devices Escape Comparative Effectiveness Study Focus With Limelight On Rx
The device industry has once again received a reprieve from comparative effectiveness trial provisions as policymakers remain centered on controlling pharmaceutical costs
Devices Escape Comparative Effectiveness Study Focus With Limelight On Rx
The device industry has once again received a reprieve from comparative effectiveness trial provisions as policymakers remain centered on controlling pharmaceutical costs
McClellan Discusses Research Alternatives To Comparative Clinical Trials
CMS Administrator Mark McClellan plans to promote healthcare information technology in an effort to decrease the number of comparative clinical studies needed to answer health outcomes-related questions